Our mission is to build the research capacity required to develop new tests and treatments for brain diseases such as Alzheimer’s. This will accelerate research for our pharmaceutical partners and increase access to new tests and medicines for patients.
Laboratory Services
In 2024, we opened an in-house biomarker laboratory at the Eden Campus, near St Andrews. Our laboratory team test samples of blood and spinal fluid for the proteins that cause Alzheimer’s disease. We will evaluate whether these tests are as accurate in detecting early disease as the current diagnostic tools, such as brain scans.
The team, led by Dr Alison Green, will soon provide a clinical diagnostic service for Alzheimer’s disease cerebrospinal fluid biomarkers, with blood biomarkers being available in 2025.
We plan to introduce biomarkers for other brain disorders, such as Parkinson’s disease, in the near future.
